Elisa Pabon1, Harriet de Wit1. 1. Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA.
Abstract
BACKGROUND: Acute consumption of cannabis or its primary psychoactive ingredient ∆9-tetrahydrocannabinol has been shown to impair memory, reaction time, time perception, and attention. However, it is difficult to measure these impairments in a brief test that can be used in a non-laboratory setting. AIMS: We aim to develop and validate a prototype for a mobile phone application to measure ∆9-tetrahydrocannabinol-induced cognitive impairment. METHODS: We conducted two double-blind, within-subjects studies examining impairments after oral doses of ∆9-tetrahydrocannabinol (0, 7.5, 15 mg) using both standardized computer-based tasks and our novel phone-based tasks. The tasks measured cognitive speed, reaction time, fine motor ability, and working memory and, in the second study, time perception. Study 1 (n=24) provided initial data, and Study 2 (n=24) was designed to refine the measures. In both studies, healthy non-daily cannabis users participated in three four-hour experimental sessions in which they received capsules containing ∆9-tetrahydrocannabinol (7.5, 15 mg) or placebo. Subjective and cardiovascular measures were obtained at regular intervals, and at the time of peak drug effect subjects completed both standardized, computer-based and brief, phone-based tasks. RESULTS: ∆9-Tetrahydrocannabinol-induced impairment was detected on most of the computer tasks, but was not evident on most of the phone tasks. CONCLUSIONS: The phone tasks were brief, to facilitate use in a non-laboratory setting, but it is likely that this made them less sensitive to the impairing effects of ∆9-tetrahydrocannabinol. These findings confirm that ∆9-tetrahydrocannabinol impairs performance on several tasks at two recreationally relevant doses, but raises question about the feasibility of designing a phone application as a sensitive field sobriety test for cannabis.
BACKGROUND: Acute consumption of cannabis or its primary psychoactive ingredient ∆9-tetrahydrocannabinol has been shown to impair memory, reaction time, time perception, and attention. However, it is difficult to measure these impairments in a brief test that can be used in a non-laboratory setting. AIMS: We aim to develop and validate a prototype for a mobile phone application to measure ∆9-tetrahydrocannabinol-induced cognitive impairment. METHODS: We conducted two double-blind, within-subjects studies examining impairments after oral doses of ∆9-tetrahydrocannabinol (0, 7.5, 15 mg) using both standardized computer-based tasks and our novel phone-based tasks. The tasks measured cognitive speed, reaction time, fine motor ability, and working memory and, in the second study, time perception. Study 1 (n=24) provided initial data, and Study 2 (n=24) was designed to refine the measures. In both studies, healthy non-daily cannabis users participated in three four-hour experimental sessions in which they received capsules containing ∆9-tetrahydrocannabinol (7.5, 15 mg) or placebo. Subjective and cardiovascular measures were obtained at regular intervals, and at the time of peak drug effect subjects completed both standardized, computer-based and brief, phone-based tasks. RESULTS: ∆9-Tetrahydrocannabinol-induced impairment was detected on most of the computer tasks, but was not evident on most of the phone tasks. CONCLUSIONS: The phone tasks were brief, to facilitate use in a non-laboratory setting, but it is likely that this made them less sensitive to the impairing effects of ∆9-tetrahydrocannabinol. These findings confirm that ∆9-tetrahydrocannabinol impairs performance on several tasks at two recreationally relevant doses, but raises question about the feasibility of designing a phone application as a sensitive field sobriety test for cannabis.
Authors: J M Stone; P D Morrison; J Nottage; S Bhattacharyya; A Feilding; P K McGuire Journal: Pharmacopsychiatry Date: 2010-07-22 Impact factor: 5.788
Authors: Erin L Karschner; David M Schwope; Eugene W Schwilke; Robert S Goodwin; Deanna L Kelly; David A Gorelick; Marilyn A Huestis Journal: Drug Alcohol Depend Date: 2012-03-29 Impact factor: 4.492
Authors: Margaret Haney; Carl L Hart; Suzanne K Vosburg; Jennifer Nasser; Andrew Bennett; Carlos Zubaran; Richard W Foltin Journal: Neuropsychopharmacology Date: 2004-01 Impact factor: 7.853
Authors: Patrik Roser; Jürgen Gallinat; Gordon Weinberg; Georg Juckel; Inge Gorynia; Andreas M Stadelmann Journal: Eur Arch Psychiatry Clin Neurosci Date: 2009-02-17 Impact factor: 5.270
Authors: Johannes G Ramaekers; Eef L Theunissen; Marjolein de Brouwer; Stefan W Toennes; Manfred R Moeller; Gerhold Kauert Journal: Psychopharmacology (Berl) Date: 2010-10-30 Impact factor: 4.530
Authors: Conor H Murray; James E Glazer; Royce Lee; Robin Nusslock; Harriet de Wit Journal: Psychopharmacology (Berl) Date: 2022-05-25 Impact factor: 4.415
Authors: Kirsten C S Adam; Manoj K Doss; Elisa Pabon; Edward K Vogel; Harriet de Wit Journal: Neuropsychopharmacology Date: 2020-05-09 Impact factor: 7.853